Two Genetic Edits That Supercharge CAR-T Cells Against Solid Tumors
The two genetic edits are knockout (loss of function) of P2RY8 and GNAS , discovered through the first ever genome wide CRISPR screen performed in human T cells inside living mice bearing solid tumors. P2RY8 knockout dramatically improves tumor infiltration by removing a molecular brake, while GNAS knockout enhances...
Δημοσιεύτηκε απόΕπεξεργασία με DeepSeek-V4-FlashΕικόνες δημιουργήθηκαν με GPT Image 1.5
The two genetic edits are knockout (loss of function) of P2RY8 and GNAS , discovered through the first ever genome wide CRISPR screen performed in human T cells inside living mice bearing solid tumors.
P2RY8 knockout dramatically improves tumor infiltration by removing a molecular brake, while GNAS knockout enhances cancer fighting activity by making T cells resistant to suppressive signals in the tumor microenviron...
Removing both P2RY8 and GNAS together produces a synergistic benefit: in a lung cancer mouse model, two thirds of mice were tumor free at the end of the study with dual edited CAR T cells, whereas none of the mice rec...
What two genetic edits, discovered through the first genome-wide CRISPR screen conducted in human T cells inside living animals, were foundA conceptual illustration of CAR-T cells in action against a solid tumor. New research identifies two genetic edits that dramatically improve their ability to infiltrate and destroy solid tumors.
AI Prompt
Create a landscape editorial hero image for this Studio Global article: What two genetic edits, discovered through the first genome-wide CRISPR screen conducted in human T cells inside living animals, were found. Article summary: The two genetic edits are knockout (loss-of-function) of **P2RY8** and **GNAS**, discovered through the first-ever genome-wide CRISPR screen performed in human T cells inside living mice bearing solid tumors. The work wa. Topic tags: general, government, academic, general web, education. Style: premium digital editorial illustration, source-backed research mood, clean composition, high detail, modern web publication hero. Use reference image context only for broad subject, composition, and topical grounding; do not copy the exact image. Avoid: logos, brand marks, copyrighted characters, real person likenesses, fake screenshots, UI text, readable text, watermarks
openai.com
CAR-T cell therapy has revolutionized the treatment of blood cancers, but solid tumors have remained a formidable challenge. The tumor microenvironment actively suppresses immune cells, preventing them from infiltrating and destroying cancer tissue. Now, scientists at Gladstone Institutes and UC San Francisco (UCSF) have discovered a pair of genetic edits that overcome these barriers, making CAR-T cells dramatically more effective against solid tumors in preclinical models .
The discovery was made possible by the first-ever genome-wide CRISPR screen performed in human T cells inside living animals. The work, led by Qi Liu, Julia Carnevale, and Alex Marson, was published in Nature in 2026 .
The Two Genetic Edits: P2RY8 and GNAS
The screen identified two genes whose knockout (loss-of-function) significantly enhances CAR-T cell performance against solid tumors: and . Each gene acts through a distinct mechanism, and combining both edits produces a powerful synergistic effect .
Studio Global AI
Continue your research
This page includes a source-backed answer you can continue inside Studio Global.
What is the short answer to "Two Genetic Edits That Supercharge CAR-T Cells Against Solid Tumors"?
The two genetic edits are knockout (loss of function) of P2RY8 and GNAS , discovered through the first ever genome wide CRISPR screen performed in human T cells inside living mice bearing solid tumors.
What are the key points to validate first?
The two genetic edits are knockout (loss of function) of P2RY8 and GNAS , discovered through the first ever genome wide CRISPR screen performed in human T cells inside living mice bearing solid tumors. P2RY8 knockout dramatically improves tumor infiltration by removing a molecular brake, while GNAS knockout enhances cancer fighting activity by making T cells resistant to suppressive signals in the tumor microenviron...
What should I do next in practice?
Removing both P2RY8 and GNAS together produces a synergistic benefit: in a lung cancer mouse model, two thirds of mice were tumor free at the end of the study with dual edited CAR T cells, whereas none of the mice rec...
Two Genetic Edits That Supercharge CAR-T Cells Against Solid Tumors
The two genetic edits are knockout (loss of function) of P2RY8 and GNAS , discovered through the first ever genome wide CRISPR screen performed in human T cells inside living mice bearing solid tumors. P2RY8 knockout dramatically improves tumor infiltration by removing a molecular brake, while GNAS knockout enhances...
Δημοσιεύτηκε απόΕπεξεργασία με DeepSeek-V4-FlashΕικόνες δημιουργήθηκαν με GPT Image 1.5
The two genetic edits are knockout (loss of function) of P2RY8 and GNAS , discovered through the first ever genome wide CRISPR screen performed in human T cells inside living mice bearing solid tumors.
P2RY8 knockout dramatically improves tumor infiltration by removing a molecular brake, while GNAS knockout enhances cancer fighting activity by making T cells resistant to suppressive signals in the tumor microenviron...
Removing both P2RY8 and GNAS together produces a synergistic benefit: in a lung cancer mouse model, two thirds of mice were tumor free at the end of the study with dual edited CAR T cells, whereas none of the mice rec...
What two genetic edits, discovered through the first genome-wide CRISPR screen conducted in human T cells inside living animals, were foundA conceptual illustration of CAR-T cells in action against a solid tumor. New research identifies two genetic edits that dramatically improve their ability to infiltrate and destroy solid tumors.
AI Prompt
Create a landscape editorial hero image for this Studio Global article: What two genetic edits, discovered through the first genome-wide CRISPR screen conducted in human T cells inside living animals, were found. Article summary: The two genetic edits are knockout (loss-of-function) of **P2RY8** and **GNAS**, discovered through the first-ever genome-wide CRISPR screen performed in human T cells inside living mice bearing solid tumors. The work wa. Topic tags: general, government, academic, general web, education. Style: premium digital editorial illustration, source-backed research mood, clean composition, high detail, modern web publication hero. Use reference image context only for broad subject, composition, and topical grounding; do not copy the exact image. Avoid: logos, brand marks, copyrighted characters, real person likenesses, fake screenshots, UI text, readable text, watermarks
openai.com
CAR-T cell therapy has revolutionized the treatment of blood cancers, but solid tumors have remained a formidable challenge. The tumor microenvironment actively suppresses immune cells, preventing them from infiltrating and destroying cancer tissue. Now, scientists at Gladstone Institutes and UC San Francisco (UCSF) have discovered a pair of genetic edits that overcome these barriers, making CAR-T cells dramatically more effective against solid tumors in preclinical models .
The discovery was made possible by the first-ever genome-wide CRISPR screen performed in human T cells inside living animals. The work, led by Qi Liu, Julia Carnevale, and Alex Marson, was published in Nature in 2026 .
The Two Genetic Edits: P2RY8 and GNAS
The screen identified two genes whose knockout (loss-of-function) significantly enhances CAR-T cell performance against solid tumors: and . Each gene acts through a distinct mechanism, and combining both edits produces a powerful synergistic effect .
Studio Global AI
Continue your research
This page includes a source-backed answer you can continue inside Studio Global.
What is the short answer to "Two Genetic Edits That Supercharge CAR-T Cells Against Solid Tumors"?
The two genetic edits are knockout (loss of function) of P2RY8 and GNAS , discovered through the first ever genome wide CRISPR screen performed in human T cells inside living mice bearing solid tumors.
What are the key points to validate first?
The two genetic edits are knockout (loss of function) of P2RY8 and GNAS , discovered through the first ever genome wide CRISPR screen performed in human T cells inside living mice bearing solid tumors. P2RY8 knockout dramatically improves tumor infiltration by removing a molecular brake, while GNAS knockout enhances cancer fighting activity by making T cells resistant to suppressive signals in the tumor microenviron...
What should I do next in practice?
Removing both P2RY8 and GNAS together produces a synergistic benefit: in a lung cancer mouse model, two thirds of mice were tumor free at the end of the study with dual edited CAR T cells, whereas none of the mice rec...
Tumors produce a molecule that activates the P2RY8 receptor on T cells, acting as a brake that physically prevents T cells from entering the tumor. Deleting P2RY8 removes this brake, causing T cells to flood into solid tumors in far greater numbers . The P2RY8 gene encodes a G protein-coupled receptor (GPCR) that, when activated, signals through Gα13 to restrict T cell trafficking. By disrupting this pathway, researchers enabled T cells to accumulate within tumors at levels unachievable with standard CAR-T cells .
Once inside the tumor, T cells face a hostile microenvironment filled with suppressive signals. GNAS (which encodes the Gαs protein) acts as a central signaling hub that processes multiple suppressive signals from the tumor microenvironment. Deleting GNAS makes T cells largely unresponsive to those signals, allowing them to maintain high production of interferon-gamma (IFN-γ), a key anti-tumor effector molecule . This makes the T cells resistant to the immunosuppressive conditions that normally cripple immune function within solid tumors.
Synergistic Combination: Infiltration and Activity
Removing both P2RY8 and GNAS together produces a synergistic benefit: the T cells both enter the tumor in greater numbers and remain highly active once inside. In a lung cancer mouse model, even at a very low CAR-T cell dose, two-thirds of mice were tumor-free at the end of the study, whereas none of the mice that received control-edited CAR-T cells cleared their tumors .
Breadth Across Solid Tumor Models
The benefits of these edits extend beyond lung cancer. CAR-T cells lacking GNAS alone shrank tumors across multiple solid tumor models, including melanoma, lung cancer, pancreatic cancer, gastroesophageal adenocarcinoma, and uterine sarcoma . The combination edits also worked when tested in T cells derived from ovarian cancer and melanoma patients, confirming translatability to patient-derived cells .
No long-term side effects were observed in mice followed for more than six months after tumor clearance, suggesting a favorable safety profile .
A New Platform for Discovery
The identification of P2RY8 and GNAS was enabled by a novel in vivo CRISPR screening platform developed by the same team. This platform allows genome-scale loss-of-function screens in primary human T cells within tumor-bearing mice, overcoming previous limitations that confined CRISPR screens to in vitro settings or required large numbers of animals . The system involves overexpressing a CD3 scFv on tumor cells to achieve high recovery of tumor-infiltrating T cells, permitting comprehensive analysis with a relatively small number of animals .
Implications for Cancer Immunotherapy
These findings represent a significant step toward making CAR-T cell therapy effective against solid tumors, which account for the vast majority of cancers. The dual-editing strategy addresses two of the most critical barriers to solid tumor immunotherapy: poor T cell infiltration and the immunosuppressive tumor microenvironment. The favorable safety profile observed in long-term mouse studies also supports further development toward clinical testing .
Tumors produce a molecule that activates the P2RY8 receptor on T cells, acting as a brake that physically prevents T cells from entering the tumor. Deleting P2RY8 removes this brake, causing T cells to flood into solid tumors in far greater numbers . The P2RY8 gene encodes a G protein-coupled receptor (GPCR) that, when activated, signals through Gα13 to restrict T cell trafficking. By disrupting this pathway, researchers enabled T cells to accumulate within tumors at levels unachievable with standard CAR-T cells .
Once inside the tumor, T cells face a hostile microenvironment filled with suppressive signals. GNAS (which encodes the Gαs protein) acts as a central signaling hub that processes multiple suppressive signals from the tumor microenvironment. Deleting GNAS makes T cells largely unresponsive to those signals, allowing them to maintain high production of interferon-gamma (IFN-γ), a key anti-tumor effector molecule . This makes the T cells resistant to the immunosuppressive conditions that normally cripple immune function within solid tumors.
Synergistic Combination: Infiltration and Activity
Removing both P2RY8 and GNAS together produces a synergistic benefit: the T cells both enter the tumor in greater numbers and remain highly active once inside. In a lung cancer mouse model, even at a very low CAR-T cell dose, two-thirds of mice were tumor-free at the end of the study, whereas none of the mice that received control-edited CAR-T cells cleared their tumors .
Breadth Across Solid Tumor Models
The benefits of these edits extend beyond lung cancer. CAR-T cells lacking GNAS alone shrank tumors across multiple solid tumor models, including melanoma, lung cancer, pancreatic cancer, gastroesophageal adenocarcinoma, and uterine sarcoma . The combination edits also worked when tested in T cells derived from ovarian cancer and melanoma patients, confirming translatability to patient-derived cells .
No long-term side effects were observed in mice followed for more than six months after tumor clearance, suggesting a favorable safety profile .
A New Platform for Discovery
The identification of P2RY8 and GNAS was enabled by a novel in vivo CRISPR screening platform developed by the same team. This platform allows genome-scale loss-of-function screens in primary human T cells within tumor-bearing mice, overcoming previous limitations that confined CRISPR screens to in vitro settings or required large numbers of animals . The system involves overexpressing a CD3 scFv on tumor cells to achieve high recovery of tumor-infiltrating T cells, permitting comprehensive analysis with a relatively small number of animals .
Implications for Cancer Immunotherapy
These findings represent a significant step toward making CAR-T cell therapy effective against solid tumors, which account for the vast majority of cancers. The dual-editing strategy addresses two of the most critical barriers to solid tumor immunotherapy: poor T cell infiltration and the immunosuppressive tumor microenvironment. The favorable safety profile observed in long-term mouse studies also supports further development toward clinical testing .
eurekalert.orgNew CRISPR screening platform boosts power of immunotherapy ...
pmc.ncbi.nlm.nih.govIn vivo genome-wide CRISPR screens in human T cells ... - PMC
pubmed.ncbi.nlm.nih.govIn vivo genome-wide CRISPR screens in human T cells to enhance ...